Medtronic Plc (MDT) concluded trading on Wednesday at a closing price of $89.0, with 4.67 million shares of worth about $415.89 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.94% during that period and on July 09, 2025 the price saw a gain of about 0.47%. Currently the company’s common shares owned by public are about 1.28B shares, out of which, 1.28B shares are available for trading.
Stock saw a price change of 0.28% in past 5 days and over the past one month there was a price change of 1.78%. Year-to-date (YTD), MDT shares are showing a performance of 14.68% which increased to 11.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $75.96 but also hit the highest price of $96.25 during that period. The average intraday trading volume for Medtronic Plc shares is 7.75 million. The stock is currently trading 1.95% above its 20-day simple moving average (SMA20), while that difference is up 4.08% for SMA50 and it goes to 2.21% higher than SMA200.
Medtronic Plc (NYSE: MDT) currently have 1.28B outstanding shares and institutions hold larger chunk of about 85.82% of that.
The stock has a current market capitalization of $114.03B and its 3Y-monthly beta is at 0.81. PE ratio of stock for trailing 12 months is 24.60, while it has posted earnings per share of $3.62 in the same period. Its PEG reads 4.43 and has Quick Ratio of 1.42 while making debt-to-equity ratio of 0.62. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MDT, volatility over the week remained 1.37% while standing at 1.47% over the month.
Stock’s fiscal year EPS is expected to rise by 1.10% while it is estimated to increase by 7.86% in next year. EPS is likely to grow at an annualized rate of 5.55% for next 5-years, compared to annual growth of 0.39% made by the stock over the past 5-years.
Coverage by Leerink Partners stated Medtronic Plc (MDT) stock as an Outperform in their note to investors on June 16, 2025, suggesting a price target of $110 for the stock. On March 04, 2025, Citigroup Upgrade their recommendations, while on October 10, 2024, RBC Capital Mkts Upgrade their ratings for the stock with a price target of $105. Stock get a Perform rating from Oppenheimer on August 21, 2024.
